Online First

July 22, 2020

Correspondence response
Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al
Free

Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim

doi: 10.1136/annrheumdis-2020-218432
Correspondence
Microbiome in Sjögren’s syndrome: here we are
Free

Taco A van der Meulen, Arjan Vissink, Hendrika Bootsma, Fred K L Spijkervet, Frans G M Kroese

doi: 10.1136/annrheumdis-2020-218213
Correspondence response
Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study’ by Goulielmos and Zervou
Free

Fang Xiao Zhu, Jing-Yang Huang, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218177
Correspondence response
Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al
Free

Julia Manasson, Rebecca B Blank, Jose U Scher

doi: 10.1136/annrheumdis-2020-218327
Correspondence response
Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al
Free

Robert B M Landewé, Hendrik Schulze-Koops

doi: 10.1136/annrheumdis-2020-218470
Correspondence
Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study
Free

George N Goulielmos, Maria I Zervou

doi: 10.1136/annrheumdis-2020-218128

July 21, 2020

Correspondence
Comment on: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
Free

Samet Karahan, Ali Cetinkaya, Kaniye Aydin, Hatice Aslan Sirakaya

doi: 10.1136/annrheumdis-2020-218497
Correspondence
COVID-19 and Behçet’s disease: clinical case series
Free

Gerard Espinosa, Olga Araujo, Sergi Amaro, Marta Bodro, Pedro Juan Moreno, Reinaldo Moreno, Ainoa Ugarte, R Cervera

doi: 10.1136/annrheumdis-2020-217778
Correspondence
COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre
Free

Natasha Cleaton, Sabrina Raizada, Nick Barkham, Srinivasan Venkatachalam, Tom Sheeran, Tochukwu Adizie, Hem Sapkota, Baldev Singh, James Bateman

doi: 10.1136/annrheumdis-2020-218236

July 15, 2020

Correspondence
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India
Free

Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, Akshat Pandey, Nikhil Gupta, Rahul Jain, Shashank Akerkar, Parthajit Das, Rajkiran Dudam, Naval Mendiratta, Bimlesh Dhar Pandey, Mithun CB, Bharat K Singh, Sharath Kumar, Nilesh Nolkha, Shriyanka Jain, Somya Jain, Ashish Sharma, Durga Prasanna Misra

doi: 10.1136/annrheumdis-2020-218013
Correspondence
Riociguat in systemic sclerosis: a potential for disease modification
Free

Siddharth Jain, Varun Dhir

doi: 10.1136/annrheumdis-2020-218180
Correspondence response
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218146
Correspondence response
Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir
Free

Dinesh Khanna, Oliver Distler

doi: 10.1136/annrheumdis-2020-218194
Correspondence
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia
Free

Samy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe

doi: 10.1136/annrheumdis-2020-218491

July 13, 2020

Correspondence response
Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace

doi: 10.1136/annrheumdis-2020-218431
Correspondence
COVID-19 in patients with rheumatic diseases: what is the real mortality risk?
Free

Claudia Marques, Marcelo M Pinheiro, Edgard Torres Reis Neto, Andrea Tavares Dantas, Francinne Machado Ribeiro, Ana Karla G Melo

doi: 10.1136/annrheumdis-2020-218388

July 10, 2020

Correspondence
‘Halo Score’: missing large-vessel giant cell arteritis— do we need a ‘modified Halo Score’?
Free

Arghya Chattopadhyay, Alakendu Ghosh

doi: 10.1136/annrheumdis-2020-218224
Correspondence response
Response to: ‘‘Halo Score’: missing large vessel giant cell arteritis– do we need a modified ‘Halo Score?’’ by Chattopadhyay and Ghosh
Free

Kornelis S M van der Geest, Bhaskar Dasgupta

doi: 10.1136/annrheumdis-2020-218262

July 09, 2020

Correspondence
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
Free

Pedro Santos-Moreno, Diana Buitrago-Garcia, Laura Villarreal, Anggie Aza, Michael Cabrera, Wilberto Rivero, Adriana Rojas-Villarraga

doi: 10.1136/annrheumdis-2020-218259

July 06, 2020

Correspondence response
Response to: ‘Comparative analysis of synovial inflammation after SARS-CoV-2 infection’ by Alivernini et al
Free

María-del-Carmen López-González, Vega Jovani, Esperanza Merino, Paloma Vela, Mariano Andrés

doi: 10.1136/annrheumdis-2020-218368
Correspondence
Comparative analysis of synovial inflammation after SARS-CoV-2 infection
Free

Stefano Alivernini, Antonella Cingolani, Marco Gessi, Annamaria Paglionico, Giuliana Pasciuto, Barbara Tolusso, Massimo Fantoni, Elisa Gremese

doi: 10.1136/annrheumdis-2020-218315
Correspondence response
Response to: ‘COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study’ by Cuceoglu et al
Free

Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Paolo Giorgi Rossi

doi: 10.1136/annrheumdis-2020-218364
Correspondence
COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study
Free

Muserref Kasap Cuceoglu, Ezgi Deniz Batu, Yelda Bilginer, Seza Özen

doi: 10.1136/annrheumdis-2020-218341
Correspondence
Should patients starting biologics be screened for COVID-19?
Free

Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado

doi: 10.1136/annrheumdis-2020-218437
Correspondence
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
Free

Maurizio Benucci, Arianna Damiani, Gianfranco Giannasi, Francesca Li Gobbi, Luca Quartuccio, Valentina Grossi, Maria Infantino, Mariangela Manfredi

doi: 10.1136/annrheumdis-2020-218214

July 03, 2020

Correspondence response
Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al
Free

Claudia Kedor, Joachim Listing, Jan Zernicke, Eugen Feist

doi: 10.1136/annrheumdis-2020-218143

July 02, 2020

Correspondence response
Response to: ‘Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland’ by Quills et al
Free

Jasvinder A Singh

doi: 10.1136/annrheumdis-2020-218263
Correspondence response
Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plüß et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218069
Correspondence
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland
Free

Neus Quilis, Paloma Vela, Boris A Blanco Cáceres, Cesar Diaz-Torne, Enrique Calvo-Aranda, Francisca Sivera, Alejandro Prada-Ojeda, Fernando Pérez Ruiz, Eliseo Pascual, Mariano Andrés

doi: 10.1136/annrheumdis-2020-218226
Correspondence response
Response to: ‘Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort’ by Costa et al
Free

Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal

doi: 10.1136/annrheumdis-2020-217953
Correspondence
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
Free

Marlene Plüß, Gamal Chehab, Peter Korsten

doi: 10.1136/annrheumdis-2020-217967

July 01, 2020

Correspondence response
Evaluating diagnostic criteria for macrophage activation syndrome in patients with adult onset Still’s disease. Response to: ‘Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease associated macrophage activation syndrome’ by Zhang et al
Free

Francesca Minoia, Angelo Ravelli

doi: 10.1136/annrheumdis-2020-218033
Correspondence
COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic
Free

Richard Oluyinka Akintayo, Akpabio Akpabio, Asgar Kalla, Dzifa Dey, Angela Migowa, Hakeem Olaosebikan, Rachid Bahiri, Yasser El Miedany, Djohra Hadef, Wafa Hamdi, Omondi Oyoo, Samy Slimani, Abubakar Yerima, Yassmin Taha, Adewale Adebajo, Olufemi Adelowo, Mohammed Tikly, Imad Ghozlani, Kawther Ben Abdelghani, Nermeen Ahmed Fouad, Doaa Mosad, Dalia El Mikkawy, Mohamed Hassan Abu-Zaid, Rasha A Abdel-Magied

doi: 10.1136/annrheumdis-2020-218273

June 30, 2020

Correspondence response
Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al
Free

Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson

doi: 10.1136/annrheumdis-2020-218328
Correspondence
Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis
Free

Andrea Hermina Györfi, Markus Kopp, Matthias May, Marcel Vetter, Michael Uder, Andreas E Kremer, Georg Schett, Thomas Harrer, Jörg H W Distler

doi: 10.1136/annrheumdis-2020-218258

June 26, 2020

Correspondence response
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
Free

Sara Monti, Carlomaurizio Montecucco

doi: 10.1136/annrheumdis-2020-218148
Correspondence
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Free

Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko

doi: 10.1136/annrheumdis-2020-218075
Correspondence response
Response to: ‘Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease’ by Akiyama et al
Free

Augusto Vaglio, Federica Maritati, Jochen Zwerina

doi: 10.1136/annrheumdis-2020-218174
Correspondence
Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease
Free

Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

doi: 10.1136/annrheumdis-2020-218124
Correspondence
Case of acute arthritis following SARS-CoV-2 infection
Free

Naoto Yokogawa, Naoto Minematsu, Harutaka Katano, Tadaki Suzuki

doi: 10.1136/annrheumdis-2020-218281

June 25, 2020

Correspondence response
Is a human in vitro enthesitis model relevant to SpA-associated enthesitis? Response to: ‘Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease’ by Alunno et al
Free

Abdulla Watad, Hannah Rowe, Darren Newton, Charlie Bridgewood, Dennis G McGonagle

doi: 10.1136/annrheumdis-2020-218151
Correspondence
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors
Free

Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, María-del-Carmen López-González, Pilar Bernabeu, Agustín Martínez, Joaquim Esteve-Vives, Jose-Manuel León-Ramírez, Oscar Moreno-Perez, Vicente Boix, Joan Gil, Esperanza Merino, Paloma Vela, Mariano Andrés

doi: 10.1136/annrheumdis-2020-218152
Correspondence
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
Free

Zoé Gendebien, Christian von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, Laurence Seidel, Michel G Malaise, Olivier Malaise

doi: 10.1136/annrheumdis-2020-218244
Correspondence response
Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace

doi: 10.1136/annrheumdis-2020-218179
Correspondence
Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic
Free

Pedro Santos-Moreno, Josefina Chavez-Chavez, Sandra Milena Hernández-Zambrano, Diana Patricia Rivera-Triana, Ruth Alexandra Castiblanco-Montañez, Anggie Aza, Diana Buitrago-Garcia, Laura Villarreal, Adriana Rojas-Villarraga

doi: 10.1136/annrheumdis-2020-218165
Correspondence response
Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al
Free

Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

doi: 10.1136/annrheumdis-2020-218193
Correspondence
Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences
Free

Jun Zhao, Rongrong Pang, Jian Wu, Yanju Guo, Yang Yang, Libo Zhang, Xinyi Xia

doi: 10.1136/annrheumdis-2020-218183
Correspondence response
Response to: ‘COVID-19 in patients with rheumatological diseases treated with Anti-TNF’ by Brito et al and ‘Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences’ by Zhao et al
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace

doi: 10.1136/annrheumdis-2020-218196

June 24, 2020

Correspondence response
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al
Free

Hendrik Schulze-Koops, Christof Specker, Klaus Krueger

doi: 10.1136/annrheumdis-2020-218235
Correspondence
Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak
Free

Ho So, Cheuk-Chun Szeto, Lai-Shan Tam

doi: 10.1136/annrheumdis-2020-218220

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

July 22, 2020

July 21, 2020

July 15, 2020

July 13, 2020

July 10, 2020

July 09, 2020

July 06, 2020

July 03, 2020

July 02, 2020

July 01, 2020

June 30, 2020

June 26, 2020

June 25, 2020

June 24, 2020

Pages